Mediwound (MDWD) to Release Quarterly Earnings on Monday

Mediwound (NASDAQ:MDWD) will be announcing its earnings results before the market opens on Monday, March 19th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Shares of Mediwound (MDWD) traded up $0.05 during trading hours on Wednesday, reaching $4.30. The company’s stock had a trading volume of 4,561 shares, compared to its average volume of 28,067. The company has a market cap of $114.95, a P/E ratio of -6.72 and a beta of 0.15. Mediwound has a 52-week low of $3.56 and a 52-week high of $8.25.

A number of research analysts have issued reports on MDWD shares. SunTrust Banks set a $9.00 price objective on Mediwound and gave the company a “buy” rating in a research note on Thursday, November 16th. Zacks Investment Research downgraded Mediwound from a “buy” rating to a “hold” rating in a research note on Tuesday, November 21st. ValuEngine upgraded Mediwound from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 25th. Finally, Oppenheimer set a $10.00 price objective on Mediwound and gave the company a “buy” rating in a research note on Friday, December 8th. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $9.13.

TRADEMARK VIOLATION NOTICE: “Mediwound (MDWD) to Release Quarterly Earnings on Monday” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at

Mediwound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Earnings History for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with's FREE daily email newsletter.

Leave a Reply